LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

45.24 -6.04

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

45.23

Макс.

48.15

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+14.54% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

212M

2.8B

Предыдущая цена открытия

51.28

Предыдущая цена закрытия

45.24

Новостные настроения

By Acuity

50%

50%

146 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 мар. 2026 г., 20:38 UTC

Отчет

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 мар. 2026 г., 23:57 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

10 мар. 2026 г., 23:57 UTC

Обсуждения рынка

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 мар. 2026 г., 23:47 UTC

Обсуждения рынка

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 мар. 2026 г., 23:37 UTC

Приобретения, слияния, поглощения

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 мар. 2026 г., 23:37 UTC

Приобретения, слияния, поглощения

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 мар. 2026 г., 23:37 UTC

Приобретения, слияния, поглощения

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 мар. 2026 г., 23:37 UTC

Приобретения, слияния, поглощения

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 мар. 2026 г., 23:35 UTC

Обсуждения рынка
Главные новостные события

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 мар. 2026 г., 23:06 UTC

Отчет

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 мар. 2026 г., 22:51 UTC

Главные новостные события

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 мар. 2026 г., 21:39 UTC

Приобретения, слияния, поглощения

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 мар. 2026 г., 21:21 UTC

Отчет

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 мар. 2026 г., 21:15 UTC

Отчет

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 мар. 2026 г., 21:15 UTC

Приобретения, слияния, поглощения

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 мар. 2026 г., 21:14 UTC

Отчет

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 мар. 2026 г., 21:13 UTC

Отчет

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 мар. 2026 г., 21:12 UTC

Отчет

Franco-Nevada 4Q Rev $597.3M >FNV

10 мар. 2026 г., 21:12 UTC

Отчет

Franco-Nevada 4Q EPS $1.90

10 мар. 2026 г., 20:57 UTC

Отчет

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

10 мар. 2026 г., 20:44 UTC

Отчет

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 мар. 2026 г., 20:34 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

10 мар. 2026 г., 20:34 UTC

Обсуждения рынка
Отчет

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 мар. 2026 г., 20:23 UTC

Отчет

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 мар. 2026 г., 20:16 UTC

Отчет

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 мар. 2026 г., 20:14 UTC

Отчет

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 мар. 2026 г., 20:14 UTC

Отчет

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 мар. 2026 г., 20:13 UTC

Отчет

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 мар. 2026 г., 20:12 UTC

Отчет

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

14.54% рост

Прогноз на 12 месяцев

Средняя 52 USD  14.54%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

146 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat